{"id":100,"date":"2023-05-22T12:51:19","date_gmt":"2023-05-22T12:51:19","guid":{"rendered":"https:\/\/roctavianhcp-dev-001.azurewebsites.net\/en-us-new\/roctavian\/?page_id=100"},"modified":"2023-12-21T09:54:25","modified_gmt":"2023-12-21T09:54:25","slug":"why-roctavian","status":"publish","type":"page","link":"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/why-roctavian\/","title":{"rendered":"Why roctavian"},"content":{"rendered":"
\n
<\/div>\n\t
<\/div>\n
\n\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t

Why Roctavian\n<\/h1>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n
\n\t
\n\t\t
\n\t\t\t
\n\t\t\t \t\t\t\t\t\t\t<\/div>\n\t\t\t
\n\t\t\t \n
\n \t \"An\t
\n

A one-time gene therapy infusion\n<\/h4>\n \n

Designed to enable patients to produce their own Factor VIII1<\/sup><\/p>\n \n <\/div>\n

\n \n

See how it works<\/a><\/p>\n <\/div>\n<\/div>\n\n

\n \t \"A\t
\n

Improved bleed control\n<\/h4>\n \n

Observed in most patients through 3 years when compared to their baseline1<\/sup><\/p>\n \n <\/div>\n

\n \n

Explore efficacy<\/a><\/p>\n <\/div>\n<\/div>\n\n

\n \t \"A\t
\n

Safety profile\n<\/h4>\n \n

The longest and largest gene therapy Phase 3 clinical trial for severe hemophilia A1<\/sup><\/p>\n \n <\/div>\n

\n \n

Review safety<\/a><\/p>\n <\/div>\n<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n

\n
\n
\n <\/div>\n <\/div>\n<\/div>\n\n
\n
\n\t\t
\n\t\t\t
\n\t\t\t\t
<\/div>\n\t\t\t\t
\n\t\t\t\t
\n \"\" <\/div>\n \t\t\t\t\t
\n
\n\t\t\t\t\t \t\t\t\t\t \t\t\t\t\t\t

Take the first steps to treatment \n<\/h2>\n\t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t <\/div>\n\t\t\t\t\t
\n

access eligibility <\/a><\/p>\n <\/div>\n\t\t\t\t\t <\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n

\n
\n\t\t
\n\t\t \t\t\t

Reference:\n<\/h4>\n\t\t\t\t\t\t
    \n
  1. ROCTAVIAN\u2122 (valoctocogene roxaparvovec-rvox). Prescribing Information. BioMarin Pharmaceutical Inc.; 2023.\n<\/span><\/li>\n <\/ol>\n\t\t\t\t\t<\/div>\n\t<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"acf":[],"yoast_head":"\nWhy ROCTAVIAN | ROCTAVIAN\u2122 (valoctocogene roxaparvovec-rvox) for Healthcare Professionals<\/title>\n<meta name=\"description\" content=\"Why ROCTAVIAN\u2122 (valoctocogene roxaparvovec-rvox)? ROCTAVIAN is a one-time gene therapy infusion for hemophilia A with 5+ years of safety whose mechanism of action enables factor VIII production, which may lead to years of improved bleed control.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/why-roctavian\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Why ROCTAVIAN | ROCTAVIAN\u2122 (valoctocogene roxaparvovec-rvox) for Healthcare Professionals\" \/>\n<meta property=\"og:description\" content=\"Why ROCTAVIAN\u2122 (valoctocogene roxaparvovec-rvox)? ROCTAVIAN is a one-time gene therapy infusion for hemophilia A with 5+ years of safety whose mechanism of action enables factor VIII production, which may lead to years of improved bleed control.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/why-roctavian\/\" \/>\n<meta property=\"og:site_name\" content=\"BioMarin Roctavian HCP EN-US\" \/>\n<meta property=\"article:modified_time\" content=\"2023-12-21T09:54:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/wp-content\/uploads\/sites\/3\/2023\/08\/ROC-HCP.png?v=0.95\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"512\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Why ROCTAVIAN | ROCTAVIAN\u2122 (valoctocogene roxaparvovec-rvox) for Healthcare Professionals\" \/>\n<meta name=\"twitter:description\" content=\"Why ROCTAVIAN\u2122 (valoctocogene roxaparvovec-rvox)? ROCTAVIAN is a one-time gene therapy infusion for hemophilia A with 5+ years of safety whose mechanism of action enables factor VIII production, which may lead to years of improved bleed control.\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/wp-content\/uploads\/sites\/3\/2023\/08\/ROC-HCP-2.png?v=1.7\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/why-roctavian\/\",\"url\":\"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/why-roctavian\/\",\"name\":\"Why ROCTAVIAN | ROCTAVIAN\u2122 (valoctocogene roxaparvovec-rvox) for Healthcare Professionals\",\"isPartOf\":{\"@id\":\"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/#website\"},\"datePublished\":\"2023-05-22T12:51:19+00:00\",\"dateModified\":\"2023-12-21T09:54:25+00:00\",\"description\":\"Why ROCTAVIAN\u2122 (valoctocogene roxaparvovec-rvox)? ROCTAVIAN is a one-time gene therapy infusion for hemophilia A with 5+ years of safety whose mechanism of action enables factor VIII production, which may lead to years of improved bleed control.\",\"breadcrumb\":{\"@id\":\"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/why-roctavian\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/why-roctavian\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/why-roctavian\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Why roctavian\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/#website\",\"url\":\"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/\",\"name\":\"BioMarin Roctavian HCP EN-US\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Why ROCTAVIAN | ROCTAVIAN\u2122 (valoctocogene roxaparvovec-rvox) for Healthcare Professionals","description":"Why ROCTAVIAN\u2122 (valoctocogene roxaparvovec-rvox)? ROCTAVIAN is a one-time gene therapy infusion for hemophilia A with 5+ years of safety whose mechanism of action enables factor VIII production, which may lead to years of improved bleed control.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/why-roctavian\/","og_locale":"en_US","og_type":"article","og_title":"Why ROCTAVIAN | ROCTAVIAN\u2122 (valoctocogene roxaparvovec-rvox) for Healthcare Professionals","og_description":"Why ROCTAVIAN\u2122 (valoctocogene roxaparvovec-rvox)? ROCTAVIAN is a one-time gene therapy infusion for hemophilia A with 5+ years of safety whose mechanism of action enables factor VIII production, which may lead to years of improved bleed control.","og_url":"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/why-roctavian\/","og_site_name":"BioMarin Roctavian HCP EN-US","article_modified_time":"2023-12-21T09:54:25+00:00","og_image":[{"width":1024,"height":512,"url":"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/wp-content\/uploads\/sites\/3\/2023\/08\/ROC-HCP.png?v=0.95","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_title":"Why ROCTAVIAN | ROCTAVIAN\u2122 (valoctocogene roxaparvovec-rvox) for Healthcare Professionals","twitter_description":"Why ROCTAVIAN\u2122 (valoctocogene roxaparvovec-rvox)? ROCTAVIAN is a one-time gene therapy infusion for hemophilia A with 5+ years of safety whose mechanism of action enables factor VIII production, which may lead to years of improved bleed control.","twitter_image":"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/wp-content\/uploads\/sites\/3\/2023\/08\/ROC-HCP-2.png?v=1.7","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/why-roctavian\/","url":"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/why-roctavian\/","name":"Why ROCTAVIAN | ROCTAVIAN\u2122 (valoctocogene roxaparvovec-rvox) for Healthcare Professionals","isPartOf":{"@id":"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/#website"},"datePublished":"2023-05-22T12:51:19+00:00","dateModified":"2023-12-21T09:54:25+00:00","description":"Why ROCTAVIAN\u2122 (valoctocogene roxaparvovec-rvox)? ROCTAVIAN is a one-time gene therapy infusion for hemophilia A with 5+ years of safety whose mechanism of action enables factor VIII production, which may lead to years of improved bleed control.","breadcrumb":{"@id":"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/why-roctavian\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/hcp.biomarin.com\/en-us\/roctavian\/why-roctavian\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/why-roctavian\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/"},{"@type":"ListItem","position":2,"name":"Why roctavian"}]},{"@type":"WebSite","@id":"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/#website","url":"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/","name":"BioMarin Roctavian HCP EN-US","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/wp-json\/wp\/v2\/pages\/100"}],"collection":[{"href":"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/wp-json\/wp\/v2\/comments?post=100"}],"version-history":[{"count":93,"href":"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/wp-json\/wp\/v2\/pages\/100\/revisions"}],"predecessor-version":[{"id":3015,"href":"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/wp-json\/wp\/v2\/pages\/100\/revisions\/3015"}],"wp:attachment":[{"href":"https:\/\/hcp.biomarin.com\/en-us\/roctavian\/wp-json\/wp\/v2\/media?parent=100"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}